Literature DB >> 32964223

Major Adverse Cardiovascular Events During Invasive Pneumococcal Disease Are Serotype Dependent.

Hector F Africano1, Cristian C Serrano-Mayorga1, Paula C Ramirez-Valbuena1, Ingrid G Bustos1, Alirio Bastidas1, Hernan A Vargas2,3, Sandra Gómez2, Alejandro Rodriguez4, Carlos J Orihuela5, Luis F Reyes1,6.   

Abstract

BACKGROUND: Up to 30% of patients admitted to hospitals with invasive pneumococcal disease (IPD) experience major adverse cardiovascular event (MACE) including new/worsening heart failure, new/worsening arrhythmia, and/or myocardial infarction. Streptococcus pneumoniae (Spn) is the most frequently isolated bacterial pathogen among community-acquired pneumonia (CAP) patients and the only etiological agent linked independently to MACE. Nevertheless, no clinical data exist identifying which serotypes of Spn are principally responsible for MACE.
METHODS: This was an observational multicenter retrospective study conducted through the Public Health Secretary of Bogotá, Colombia. We included patients with a confirmed clinical diagnosis of IPD with record of pneumococcal serotyping and clinical information between 2012 and 2019. Spn were serotyped using the quellung method by the National Center of Microbiology. MACE were determined by a retrospective chart review.
RESULTS: The prevalence of MACE was 23% (71/310) in IPD patients and 28% (53/181) in patients admitted for CAP. The most prevalent S. pneumoniae serotype identified in our study was the 19A, responsible for the 13% (42/310) of IPD in our cohort, of which 21% (9/42) presented MACE. Serotypes independently associated with MACE in IPD patients were serotype 3 (odds ratio [OR] 1, 48; 95% confidence interval [CI] [1.21-2.27]; P = .013) and serotype 9n (OR 1.29; 95% CI [1.08-2.24]; P = .020). Bacteremia occurred in 87% of patients with MACE. Moreover, serum concentrations of C-reactive protein were elevated in patients with MACE versus in non-MACE patients (mean [standard deviation], 138 [145] vs 73 [106], P = .01).
CONCLUSIONS: MACE are common during IPD with serotype 3 and 9n independently of frequency.
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  zzm321990 Streptococcus pneumoniae (Spn); invasive pneumococcal disease (IPD); major adverse cardiovascular events (MACE); serotypes

Mesh:

Substances:

Year:  2021        PMID: 32964223      PMCID: PMC8599727          DOI: 10.1093/cid/ciaa1427

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  37 in total

1.  Factors influencing long-term survival after hospitalization with pneumococcal pneumonia.

Authors:  Luis A Ruiz; Leyre Serrano; Pedro P España; Lorea Martinez-Indart; Ainhoa Gómez; Ane Uranga; Sonia Castro; Amaia Artaraz; Rafael Zalacain
Journal:  J Infect       Date:  2019-11-05       Impact factor: 6.072

Review 2.  Acute pneumonia and the cardiovascular system.

Authors:  Vicente F Corrales-Medina; Daniel M Musher; Svetlana Shachkina; Julio A Chirinos
Journal:  Lancet       Date:  2013-01-16       Impact factor: 79.321

Review 3.  Cardiovascular complications following pneumonia: focus on pneumococcus and heart failure.

Authors:  Benjamin Bartlett; Herbert P Ludewick; Silvia Lee; Girish Dwivedi
Journal:  Curr Opin Cardiol       Date:  2019-03       Impact factor: 2.161

4.  Infiltrated Macrophages Die of Pneumolysin-Mediated Necroptosis following Pneumococcal Myocardial Invasion.

Authors:  Ryan P Gilley; Norberto González-Juarbe; Anukul T Shenoy; Luis F Reyes; Peter H Dube; Marcos I Restrepo; Carlos J Orihuela
Journal:  Infect Immun       Date:  2016-04-22       Impact factor: 3.441

Review 5.  Host genetic susceptibility to pneumococcal and meningococcal disease: a systematic review and meta-analysis.

Authors:  Matthijs C Brouwer; Jan de Gans; Sebastiaan G B Heckenberg; Aeilko H Zwinderman; Tom van der Poll; Diederik van de Beek
Journal:  Lancet Infect Dis       Date:  2008-11-25       Impact factor: 25.071

6.  Early and Late Cardiovascular Events in Patients Hospitalized for Community-Acquired Pneumonia.

Authors:  Irene Aldás; Rosario Menéndez; Raúl Méndez; Pedro Pablo España; Jordi Almirall; Luis Boderías; Olga Rajas; Rafael Zalacaín; Montserrat Vendrell; Isabel Mir; Antoni Torres
Journal:  Arch Bronconeumol (Engl Ed)       Date:  2019-11-30       Impact factor: 4.872

7.  Cardiovascular complications of acute respiratory infections: current research and future directions.

Authors:  Jennifer A Davidson; Charlotte Warren-Gash
Journal:  Expert Rev Anti Infect Ther       Date:  2019-11-08       Impact factor: 5.091

8.  A Non-Human Primate Model of Severe Pneumococcal Pneumonia.

Authors:  Luis F Reyes; Marcos I Restrepo; Cecilia A Hinojosa; Nilam J Soni; Anukul T Shenoy; Ryan P Gilley; Norberto Gonzalez-Juarbe; Julio R Noda; Vicki T Winter; Melissa A de la Garza; Robert E Shade; Jacqueline J Coalson; Luis D Giavedoni; Antonio Anzueto; Carlos J Orihuela
Journal:  PLoS One       Date:  2016-11-17       Impact factor: 3.240

9.  Prognostic factors associated with mortality and major in-hospital complications in patients with bacteremic pneumococcal pneumonia: Population-based study.

Authors:  Jessica A Beatty; Sumit R Majumdar; Gregory J Tyrrell; Thomas J Marrie; Dean T Eurich
Journal:  Medicine (Baltimore)       Date:  2016-11       Impact factor: 1.889

10.  A New Pneumococcal Capsule Type, 10D, is the 100th Serotype and Has a Large cps Fragment from an Oral Streptococcus.

Authors:  Feroze Ganaie; Jamil S Saad; Lesley McGee; Andries J van Tonder; Stephen D Bentley; Stephanie W Lo; Rebecca A Gladstone; Paul Turner; Jeremy D Keenan; Robert F Breiman; Moon H Nahm
Journal:  mBio       Date:  2020-05-19       Impact factor: 7.867

View more
  7 in total

Review 1.  Effect of Pneumococcal Vaccine on Mortality and Cardiovascular Outcomes: A Systematic Review and Meta-Analysis.

Authors:  Vikash Jaiswal; Song Peng Ang; Kriti Lnu; Angela Ishak; Nishan Babu Pokhrel; Jia Ee Chia; Adrija Hajra; Monodeep Biswas; Andrija Matetic; Ravinder Dhatt; Mamas A Mamas
Journal:  J Clin Med       Date:  2022-06-30       Impact factor: 4.964

2.  Host- and Pathogen-Related Factors for Acute Cardiac Events in Pneumococcal Pneumonia.

Authors:  Alexander Rombauts; Gabriela Abelenda-Alonso; Jordi Càmara; Laia Lorenzo-Esteller; Aida González-Díaz; Enric Sastre-Escolà; Carlota Gudiol; Jordi Dorca; Cristian Tebé; Natàlia Pallarès; Carmen Ardanuy; Jordi Carratalà
Journal:  Open Forum Infect Dis       Date:  2020-10-26       Impact factor: 3.835

Review 3.  Sugar-Coated Killer: Serotype 3 Pneumococcal Disease.

Authors:  Jennifer N Luck; Hervé Tettelin; Carlos J Orihuela
Journal:  Front Cell Infect Microbiol       Date:  2020-12-23       Impact factor: 5.293

4.  Pneumococcal serotypes causing non-invasive pneumonia in adults from a South Indian tertiary care hospital and the impact of the newer conjugate vaccines.

Authors:  Rosemol Varghese; Binesh Lal Yesudhason; Leena Robinson Vimala; Ayyanraj Neeravi; Kavipriya Anandhan; Pavithra Baskar; Divyaa Elangovan; Abi Manesh; Prince James; Richa Gupta; Balaji Veeraraghavan
Journal:  Access Microbiol       Date:  2021-12-07

5.  Serotype-specific Cardiac Involvement in Pneumococcal Pneumonia.

Authors:  Keith P Klugman; Charles Feldman
Journal:  Clin Infect Dis       Date:  2022-02-11       Impact factor: 9.079

Review 6.  Multi-Valent Protein Hybrid Pneumococcal Vaccines: A Strategy for the Next Generation of Vaccines.

Authors:  Ninecia R Scott; Beth Mann; Elaine I Tuomanen; Carlos J Orihuela
Journal:  Vaccines (Basel)       Date:  2021-03-02

Review 7.  [Pneumococcal vaccination].

Authors:  Mathias W Pletz; Christina Bahrs
Journal:  Internist (Berl)       Date:  2021-07-12       Impact factor: 0.743

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.